About this Research Topic
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. In 2020, it had been estimated that about 150,000 persons will be newly diagnosed with CRC in United States, with a rate of incidence increasing in individuals aged younger than 50 years. Despite the majority of CRC being sporadic, developing as a consequence of alterations in genes mainly involved in cell growth-regulation, colon cancer has been also associated with chronic colonic inflammation that prompts tissues to genomic instability. Furthermore, it is well established that gut microbiota composition is strictly correlated to colon carcinogenesis, although it is still unclear its specific role.
In this context, this Research Topic will include studies on specific molecular protein and novel pathways involved in colon carcinogenesis that may be targeted for personalized precision medicine. Indeed, the patient genomic profile is crucial to figuring out their individual cancer in order to facilitate the pharmacological treatments and improve patient outcomes.
This Research Topic aims also to collect detailed studies about the influence of gut microbiota composition in the pathogenesis of colon cancer and about any pharmacological treatment relevant to this field.
Lastly, since metabolic remodeling is absolutely required for the malignant transformation of cells, the Research Topic will also include manuscripts on novel antineoplastic approaches targeting specific metabolic pathways.
This Article Collection will include Original Research Articles and Reviews focusing on novel drugs or new targets for drug development in the sporadic colon cancer and colitis-associated cancer.
Specifically, manuscripts in the following sub-areas (but not limited to) are highly encouraged:
• colon cancer metabolism,
• role of gut microbiota in colon cancer,
• targeted therapy,
• mechanistic studies on mode of action of new drugs,
• new formulations of molecules already used in colon cancer
• synthesis and characterization of novel drugs (only data supported by pharmacological results)
In this context, this Research Topic will include studies on specific molecular protein and novel pathways involved in colon carcinogenesis that may be targeted for personalized precision medicine. Indeed, the patient genomic profile is crucial to figuring out their individual cancer in order to facilitate the pharmacological treatments and improve patient outcomes.
This Research Topic aims also to collect detailed studies about the influence of gut microbiota composition in the pathogenesis of colon cancer and about any pharmacological treatment relevant to this field.
Lastly, since metabolic remodeling is absolutely required for the malignant transformation of cells, the Research Topic will also include manuscripts on novel antineoplastic approaches targeting specific metabolic pathways.
This Article Collection will include Original Research Articles and Reviews focusing on novel drugs or new targets for drug development in the sporadic colon cancer and colitis-associated cancer.
Specifically, manuscripts in the following sub-areas (but not limited to) are highly encouraged:
• colon cancer metabolism,
• role of gut microbiota in colon cancer,
• targeted therapy,
• mechanistic studies on mode of action of new drugs,
• new formulations of molecules already used in colon cancer
• synthesis and characterization of novel drugs (only data supported by pharmacological results)
Keywords: Colorectal cancer, colitis-associated cancer, targeted therapy, gut microbiota, cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
